Milan Sanghavi, MD
Neurology · Pasadena, MDNPI 1497967277
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $117,065 of the $144,674 with a category attached, or 80.9%. 60 manufacturers reported payments, led by Lilly USA, LLC at 36.5% of the total. 2025 is the largest year on record at $45,688, more than ten times the $2,408 reported in 2019. Among neurology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,343 payments — averaging $107.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$53K
- AbbVie$50K
- Biohaven Pharmaceutical Holding Company Ltd.$13K
- Biohaven Pharmaceuticals, Inc.$7K
- Pfizer$5K
- Novartis$2K
- plus $14K from 54 others
What the payments were for
- Consulting fees$1,5251%
- Speaking & faculty fees$117,06581%
- Travel & lodging$3,2162%
- Food & beverage$22,76416%
- Education$1040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$46,093
- KISUNLA$31,254
- NURTEC ODT$23,993
- QULIPTA$8,785
How this compares
$144,674 in reported general payments places this provider in the 95th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 64 | $1,136,162 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 41 | $1,114,775 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 26 | $772,361 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 44 | $653,461 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 13 | $463,757 |
| AptiomEslicarbazepine Acetate | 45 | $129,178 |
| NuplazidPimavanserin Tartrate | 19 | $127,408 |
| VumerityDiroximel Fumarate | 12 | $111,474 |
| CopaxoneGlatiramer Acetate | 13 | $74,599 |
| Nurtec OdtRimegepant Sulfate | 48 | $48,959 |
| Aimovig AutoinjectorErenumab-Aooe | 42 | $43,900 |
| RexultiBrexpiprazole | 15 | $36,945 |
| GocovriAmantadine Hcl | 18 | $29,517 |
| Emgality PenGalcanezumab-Gnlm | 32 | $26,303 |
| QuliptaAtogepant | 21 | $23,723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga, Nurtec Odt | $5,306 | $1,163,73489 claims |
| Grifols USA, LLCGamunex-C | $456 | $1,136,16264 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $469 | $772,36126 claims |
| CSL BehringPrivigen | $430 | $653,46144 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $741 | $129,17845 claims |
| Acadia Pharmaceuticals IncNuplazid | $332 | $127,40819 claims |
| BiogenVumerity | $1,240 | $111,47412 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $523 | $74,59913 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $93 | $36,94515 claims |
| MDD US Operations, LLCGocovri | $88 | $29,51718 claims |
| AbbVieQulipta | $50,487 | $23,72321 claims |
| Axsome Therapeutics, Inc.Sunosi | $210 | $11,16013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 442 neurology providers in Maryland.
Other neurology in Pasadena
- Daniel BeckerLutherville$1.6M
- Sangjin OhGlen Burnie$1.5M
- Pavel KleinBethesda$709K
- Ruwani GunawardaneFulton$479K
- Michael PolydefkisBaltimore$371K
- David CornblathLutherville$345K
- Shiv SaidhaBaltimore$298K
- Santiago Mazuera MesiaBaltimore$258K
- Bruce RabinLutherville$228K
- Thomas CrawfordBaltimore$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.